Multiple Tumor-Associated Antigens on T Lymphocytes

This target designation is incorrect and incoherent as a single therapeutic target. Tumor-associated antigens (TAAs) are expressed on tumor cells, not on T lymphocytes, which are immune cells that recognize these antigens. Furthermore, 'Multiple tumor-associated antigens' refers to a diverse class of antigens, not a discrete molecular entity. While TAAs are crucial targets for immunotherapy (as epitopes recognized by T cells), they are not considered traditional therapeutic targets like receptors or enzymes. This designation may have mistakenly referred to autologous tumor-associated antigen-specific cytotoxic T lymphocytes (a cellular therapeutic product), T cell receptors (TCRs) themselves (molecular targets in TCR-T therapies), or specific tumor antigens (e.g., WT1, PRAME, survivin).